Previous 10 | Next 10 |
2023-12-15 18:06:45 ET Thanks to a shareholder-pleasing move, Cassava Sciences (NASDAQ: SAVA) stock was an outperformer in the biotech sector this week. Over the period, the company's shares gained 21% in value, according to data compiled by S&P Global Market Intelligence . ...
2023-12-12 14:02:18 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Shares of pharmaceutical specialist Cassava Sciences (NASDAQ: SAVA ) soared earlier Tuesday before giving up most of the gains. Nevertheless, investor enthusiasm spiked over managem...
2023-12-12 12:15:42 ET More on Cassava Sciences Cassava Sciences - How To Interpret 3 'Positive' Updates Shared In Q3 Cassava Sciences: Likely Potential Opportunity From Phase 3 Readout Next Year Cassava Sciences' Simufilam Does Not Appear To Be Effective Against Alz...
Shareholders of Record Will Receive Warrants to Purchase Shares of Common Stock All Warrants to Be Distributed to Shareholders Free of Charge Warrants Are Expected to List and Trade on Nasdaq Warrant Holders Who Choose to Exercise During an Early Period Will Also Receive a...
AUSTIN, Texas, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced the appointment of three new members to its Board of Directors, effective immediately. Claude Nicaise, MD ...
2023-12-06 17:03:31 ET Summary Cassava's stock price has experienced significant losses, down 40% on a 12-month basis and 29% year-to-date. The company reported a cash position of $142.4m in Q3 2023, indicating sufficient funds to complete its Phase 3 studies. Positive updates...
2023-12-05 03:58:10 ET Summary Investing in most current Alzheimer's drug companies is not recommended because they are not likely to modify the disease. Compounds that inhibit oxidative stress may only slow down the progression of Alzheimer's disease over the short term. Anav...
2023-11-20 03:15:43 ET Summary Cassava Sciences is a biotech company focused on developing treatments for Alzheimer's disease with its lead drug candidate, Simufilam. The company has faced allegations of data manipulation and misconduct, but no concrete evidence has been found to ...
2023-11-17 05:55:00 ET Summary Biotech sector faces challenges including higher interest rates, inflation, regulatory pressures, and a post-COVID slump. Short interest remains high for some pharmaceutical companies, indicating bearish sentiment. Exchange-traded funds in the bi...
2023-11-17 03:45:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
News, Short Squeeze, Breakout and More Instantly...
Cassava Sciences, Inc. (NASDAQ: SAVA) is one of today's top gainers. The company's shares have moved 24.9% on the day to $12.59. Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 6.6% to $117.99 on volume of 383,510,118 shares Aptevo Therapeutics Inc. (APVO) rose 73.4% to $0.581 on volume of 315,289,581 shares PROSHARES TRUST (SQQQ) rose 8.7% to $8.11 on volume of 173,682,364 sha...
A look at the top 10 most actives in the United States Aptevo Therapeutics Inc. (APVO) rose 45.1% to $0.486 on volume of 64,992,551 shares Verb Technology Company Inc. (VERB) rose 3.5% to $0.1205 on volume of 54,410,242 shares NVIDIA Corporation (NVDA) fell 4.4% to $120.752 on volume of 4...